Released Nov 4, 2026, after the close
10-Q filed Nov 4, 2026, 35 days after period end · 0001193125-26-447364
OPKO enters into agreement with Labcorp for the sale of substantially all remaining BioReference diagnostic operations.
The release| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $65.41M | $56.43M | $173.63M | $178.60M |
| Net Income | -$53.53M | $21.63M | $24.89M | -$84.47M |
Opko Health, Inc. · CIK 944809 · Engraved from SEC EDGAR
| EPS Diluted | -$0.07 | $0.03 | $0.03 | -$0.11 |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OPKO entered into an agreement with Labcorp to sell substantially all remaining BioReference diagnostic operations for $722 million in cash at closing, plus up to $150 million over up to ten years.¶1
OPKO issued an additional $125 million aggregate principal amount of senior secured royalty notes, expanding its strategic relationship with HealthCare Royalty.¶2
Revenue from continuing operations in the third quarter of 2026 increased 16% to $65.4 million from $56.4 million, and net loss from continuing operations was $35.5 million, or $0.05 per share.¶3
Due to the pending Labcorp transaction, OPKO withdrew its previously issued guidance for services revenue and total costs and expenses, and will continue to provide guidance for continuing operations.¶4
OPKO repurchased 7,050,000 shares during the quarter for approximately $10.6 million, leaving approximately $84.3 million available under the $200 million share repurchase authorization.¶5